You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

265 Results
Regimen
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Liposomal Daunorubicin and Liposomal Cytarabine (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Dec 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
Exceptional Access Program
    lenvatinib - For the treatment of unresectable advanced hepatocellular carcinoma according to clinical criteria
Mar 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Drugs Used:
binimetinib (Unfunded),
encorafenib (Unfunded),
cetuximab (Unfunded)
Jul 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
Jun 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Jun 2020
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Apr 2023
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Apr 2023
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Jul 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
Sep 2023

Pages